Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Science

NanoHybrids Inc. Launches its First Product Line of Imaging Contrast Agents


Print article Print article

Silica-coated Gold Nanoparticles. Peak Wavelength Options: 780 nm, 808 nm, 850 nm, 1064 nm.
Silica-coated Gold Nanoparticles. Peak Wavelength Options: 780 nm, 808 nm, 850 nm, 1064 nm.
2014-03-06 15:31:31 - Our premium gold nanoparticles can enhance biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. Our products can potentially be employed in a wide variety of applications including optical biomedical imaging, microscopy, molecular diagnostics and theranostic approaches.

NanoHybrids Corporation, a provider of nanotechnology-based contrast agents announced the launch of its new website and premium product line of gold nanoparticles specially designed to improve imaging results. The company’s initial technology platform was developed in collaboration with researchers from the Biomedical Engineering Department at The University of Texas at Austin and M.D. Anderson Cancer Center.

“Frustrated by inconsistent imaging results due to highly variable shape, size and other properties of commercially available gold nanoparticle contrast agents, our team has developed highly monodisperse gold nanorods and nanospheres that will help scientists obtain consistent and better quality data. We also have a policy of ‘no proprietary coatings’ which means that unlike some companies in this space, we offer full transparency on

surface chemistry, making it easier for our customers to modify and use these particles depending on their application,” says Co-founder and Chief Technology Officer Dr. Kimberly Homan.

NanoHybrids’ offerings include an exclusive line of silica-coated gold nanorods that are quickly gaining popularity as contrast agents in photoacoustic (optoacoustic) imaging. As opposed to current preclinical imaging contrast agents on the market, NanoHybrids’ silica-coated nanorods resist melting and shape distortion even when subjected to extreme heat via focused laser beams. In addition to providing this enhanced thermodynamic stability, the silica-coating also facilitates better heat transfer to the surrounding fluid, thus dramatically increasing signal strength. Overall, these benefits make the company’s silica-coated gold nanorods an excellent contrast agent for not only in vitro and in vivo photoacoustic imaging but also many other applications involving continuous or pulsed lasers.

The founders at NanoHybrids have decades of experience in biomedical imaging and have been pioneering the development of contrast agents alongside custom designed imaging systems. “Our products have been developed by imaging researchers, for researchers. As scientists ourselves, we understand the challenges involved when working with gold nanoparticles in imaging and strive to provide the highest possible level of quality and technical support,” says Homan.

About NanoHybrids: NanoHybrids Inc. is an Austin-based company focused on commercializing nanotechnology solutions that can enhance the non-invasive detection and molecular profiling of cancer, atherosclerosis and other diseases. The company’s current product line comprises of nano-sized agents that enhance contrast in pre-clinical biomedical imaging techniques by interacting specifically with diseased cells and allowing for selective real-time imaging of functional biology.

Website: www.nanohybrids.net
Product Applications: nanohybrids.net/pages/applications
Products: nanohybrids.net/collections/all-products

Contact information: info at nanohybrids.net





Press Information:
NanoHybrids

3112 Windsor Rd. Ste. A #352
Austin, TX 78703-2350

Contact Person:
Nishi Viswanathan
Director, Product Development
Phone: 512-270-8469
email: email

Web: www.nanohybrids.net

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com